Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $21.5 million.

  • Cartesian Therapeutics' Operating Expenses rose 1979.73% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.6 million, marking a year-over-year decrease of 872.27%. This contributed to the annual value of $82.8 million for FY2024, which is 2633.87% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Operating Expenses of $21.5 million as of Q3 2025, which was up 1979.73% from $22.1 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Operating Expenses ranged from a high of $44.6 million in Q4 2023 and a low of $18.0 million during Q3 2024
  • Moreover, its 5-year median value for Operating Expenses was $23.0 million (2025), whereas its average is $23.6 million.
  • In the last 5 years, Cartesian Therapeutics' Operating Expenses surged by 7633.94% in 2023 and then crashed by 4176.42% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Operating Expenses (Quarter) stood at $25.9 million in 2021, then dropped by 2.2% to $25.3 million in 2022, then skyrocketed by 76.34% to $44.6 million in 2023, then tumbled by 41.76% to $26.0 million in 2024, then dropped by 17.15% to $21.5 million in 2025.
  • Its Operating Expenses stands at $21.5 million for Q3 2025, versus $22.1 million for Q2 2025 and $23.0 million for Q1 2025.